Metastatic colorectal cancer is diagnosed and staged with stunning speed and detail, yet the pathways to that diagnosis can look very different patient to patient. For example, 75% of mCRC is already stage IV at first imaging, and CEA levels rise more than 20-fold as the disease progresses. We’ll connect these headline figures to what imaging, biomarker tests, and survival outcomes imply in real life, including why PET CT, ctDNA, and molecular profiling can change management for a surprising share of people.
Key Takeaways
- 75% of mCRC diagnosed at stage IV via CT/MRI showing liver mets >1cm
- CEA >5 ng/mL in 80% mCRC at diagnosis, rises >20x with progression
- Liver is primary metastasis site in 65% mCRC, detected by contrast CT (sensitivity 85%)
- In 2023, an estimated 152,810 new cases of colorectal cancer were diagnosed in the US, with approximately 23% presenting as metastatic at diagnosis
- Globally, colorectal cancer accounts for 10.2% of all cancer incidences in 2020, with metastatic stage IV comprising about 25% of cases
- The age-adjusted incidence rate of metastatic colorectal cancer in the US is 4.5 per 100,000 population for ages 50-64
- 30% of mCRC cases harbor KRAS mutations, conferring resistance to EGFR inhibitors
- BRAF V600E mutation occurs in 8-12% mCRC, linked to 4x worse prognosis and MSI-H
- MSI-high/dMMR phenotype in 4% mCRC, 15% right-sided, predicts immunotherapy response
- Median overall survival for untreated metastatic colorectal cancer is 5-6 months
- 5-year overall survival rate for metastatic CRC is 14.9% (US SEER 2014-2020)
- With first-line FOLFOX + bevacizumab, median PFS is 9.4 months in mCRC
- Median PFS with FOLFOXIRI + bevacizumab is 12.1 months in mCRC
- Cetuximab + irinotecan in KRAS wt refractory mCRC: ORR 22.5%
- Encorafenib + cetuximab in BRAF V600E mCRC: ORR 26%, PFS 4.3 months
Most metastatic colorectal cancer is diagnosed at stage IV with liver spread, where advanced imaging and biomarkers guide treatment.
Related reading
01 · Category
Diagnosis and Staging22 stats
01
75% of mCRC diagnosed at stage IV via CT/MRI showing liver mets >1cm
02
CEA >5 ng/mL in 80% mCRC at diagnosis, rises >20x with progression
03
Liver is primary metastasis site in 65% mCRC, detected by contrast CT (sensitivity 85%)
04
PET-CT changes management in 20-30% mCRC staging, sensitivity 92% for mets
05
Circulating tumor DNA (ctDNA) detects mCRC recurrence at 87% sensitivity pre-imaging
06
Synchronous mets in 20-25% CRC at diagnosis vs 50% metachronous within 3 years
07
Lung mets in 15-20% mCRC, best staged by chest CT (sensitivity 90%)
08
Peritoneal carcinomatosis (PCI>10) in 25% mCRC, diagnosed by CT/DWI-MRI
09
RAS testing mandatory pre-anti-EGFR, NGS panels cover 100% hotspots
10
MSI/MMR IHC on biopsy: 95% concordance with PCR for dMMR detection
11
Endoscopic ultrasound for rectal mCRC staging: T/N accuracy 85%/70%
12
Diffusion-weighted MRI detects peritoneal mCRC lesions <1cm (sens 90%)
13
Liquid biopsy ctDNA MRD post-resection predicts relapse at 91% NPV
14
Bone mets rare (10%) in mCRC, FDG-PET sensitivity 93% vs bone scan 66%
15
Primary tumor sidedness: left 65% mCRC vs right 35%, prognostic via biopsy
16
Multiplex IHC (CDX2/HER2) refines mCRC subtype in 95% cases
17
18F-FDG PET SUVmax >9 predicts poor mCRC prognosis (staging tool)
18
Brain mets in 4% mCRC, MRI gadolinium sensitivity 98% for detection
19
Circulating tumor cells ≥3/7.5mL blood indicate mCRC stage IV (sens 76%)
20
NGS identifies actionable alterations in 20% refractory mCRC for trials
21
Contrast-enhanced US for liver mets: sensitivity 96% small lesions
22
Fecal immunochemical test (FIT) detects 70% early CRC but <20% mCRC
Interpretation
Diagnosis and Staging Interpretation
Here’s a liver that’s frankly hogging the spotlight, as metastatic colorectal cancer, with its predictable plot twists and rising CEA soundtrack, reveals itself through a cascade of scans and molecular whispers long before it shows up for its main imaging debut.
02 · Category
Epidemiology30 stats
01
In 2023, an estimated 152,810 new cases of colorectal cancer were diagnosed in the US, with approximately 23% presenting as metastatic at diagnosis
02
Globally, colorectal cancer accounts for 10.2% of all cancer incidences in 2020, with metastatic stage IV comprising about 25% of cases
03
The age-adjusted incidence rate of metastatic colorectal cancer in the US is 4.5 per 100,000 population for ages 50-64
04
In Europe, the 5-year prevalence of metastatic colorectal cancer reached 1.2 million cases by 2022
05
Among US Hispanics, metastatic colorectal cancer incidence rose 2.1% annually from 2012-2021
06
In Asia, metastatic colorectal cancer cases increased by 45% from 2008 to 2018 due to westernized diets
07
The lifetime risk of developing metastatic colorectal cancer synchronously is 22% for all CRC diagnoses
08
In 2024 projections, Australia expects 1,200 new metastatic colorectal cancer cases
09
US men have a 1.4 times higher incidence of metastatic CRC than women (5.2 vs 3.7 per 100,000)
10
From 2015-2020, metastatic CRC incidence in young adults (20-49) increased by 1.5% per year
11
In China, metastatic colorectal cancer represents 28% of all CRC cases with 250,000 annual incidences
12
UK data shows metastatic CRC prevalence at 45,000 patients under active treatment in 2022
13
African Americans face a 20% higher metastatic CRC incidence rate (6.1 per 100,000) vs whites
14
Globally, 1.93 million CRC cases in 2020, 500,000 metastatic
15
In Japan, metastatic CRC incidence doubled from 1993-2018 to 15,000 cases/year
16
US rural areas report 15% higher metastatic CRC rates than urban (5.8 vs 5.0 per 100,000)
17
Women under 50 saw metastatic CRC incidence rise 3.2% annually 2009-2018
18
In India, metastatic CRC cases grew 5-fold from 2001-2020 to 50,000 annually
19
Canada’s metastatic CRC incidence stabilized at 4.2 per 100,000 post-2015 screening
20
Brazil reports 40,000 metastatic CRC cases yearly, 26% of total CRC
21
In the EU, metastatic CRC mortality exceeds 150,000/year despite declining incidence
22
US veterans have 1.8-fold higher metastatic CRC risk (7.2 per 100,000)
23
Middle East metastatic CRC incidence at 3.5 per 100,000, rising 4% yearly
24
In 2022, 70,000 US patients lived with metastatic CRC >5 years post-diagnosis
25
Australia’s Indigenous population has 2.5x metastatic CRC incidence (9.0 per 100,000)
26
From 2010-2020, global metastatic CRC burden increased 32% to 900,000 DALYs
27
In South Korea, metastatic CRC in under-50s tripled to 12% of cases 2006-2015
28
France reports 18,000 new metastatic CRC diagnoses annually (2023)
29
US obese population (BMI>30) has 1.3x metastatic CRC incidence risk
30
In 2021, metastatic CRC accounted for 50% of CRC healthcare costs ($10B in US)
Interpretation
Epidemiology Interpretation
While colorectal cancer often announces itself with the quiet betrayal of a late-stage diagnosis, a sobering 500,000 people worldwide each year are handed a metastatic label that underscores the urgent need for better screening and dietary awareness.
03 · Category
Risk Factors and Genetics30 stats
01
30% of mCRC cases harbor KRAS mutations, conferring resistance to EGFR inhibitors
02
BRAF V600E mutation occurs in 8-12% mCRC, linked to 4x worse prognosis and MSI-H
03
MSI-high/dMMR phenotype in 4% mCRC, 15% right-sided, predicts immunotherapy response
04
HER2 amplification in 3-5% mCRC, associated with KRAS/NRAS/BRAF wild-type
05
PIK3CA mutations in 15-20% mCRC, correlate with poor response to anti-EGFR therapy
06
APC gene mutations in 70-80% mCRC, initiating adenoma-carcinoma sequence
07
Family history increases mCRC risk 2-4 fold, Lynch syndrome 40-80% lifetime risk
08
Obesity (BMI ≥30) raises mCRC risk by 1.3x, mediated by hyperinsulinemia
09
Smoking >20 pack-years doubles mCRC risk via DNA methylation changes
10
Type 2 diabetes increases mCRC risk 1.3-fold, via IGF-1 and inflammation
11
Red/processed meat intake >500g/week elevates mCRC risk 17%, heme iron nitrosamines
12
Alcohol >30g/day raises mCRC risk 1.5x, acetaldehyde DNA adducts
13
Inflammatory bowel disease (UC/Crohn's) confers 2x mCRC risk after 10 years
14
Aspirin use >10 years reduces mCRC risk by 30%, COX-2 inhibition
15
NRAS mutations in 3-5% mCRC, similar resistance to anti-EGFR as KRAS
16
TP53 mutations in 60% mCRC, associated with aggressive phenotype
17
Low physical activity (<150 min/week) increases mCRC risk 24%
18
Hypercholesterolemia raises mCRC metastasis risk via SREBP pathway
19
Lynch syndrome (MLH1/MSH2/MSH6/PMS2) causes 3% hereditary mCRC
20
MET amplification in 1-2% mCRC, potential resistance biomarker
21
Chronic NSAID use reduces mCRC risk 40% in FAP patients
22
High serum 25(OH)D >30 ng/mL lowers mCRC risk 50%
23
RET fusions in <1% mCRC, targetable with selpercatinib
24
NTRK fusions rare (0.5%) in mCRC, respond to larotrectinib ORR 75%
25
Hypermutated tumors (>10 mut/Mb) in 5% mCRC, immunotherapy sensitive
26
STAT3 activation in 50% mCRC, promotes metastasis via EMT
27
Estrogen receptor beta loss increases mCRC risk in women
28
Familial adenomatous polyposis (APC germline) leads to 100% CRC risk by 40s
29
CIMP-high phenotype in 15% right-sided mCRC, overlaps BRAF mut/MSI-H
30
Serum VEGF levels >100 pg/mL predict higher mCRC metastasis risk
Interpretation
Risk Factors and Genetics Interpretation
Between the sobering genetic roulette of KRAS mutations making treatments futile and the preventable dangers of lifestyle choices, colorectal cancer is both a cruel genetic betrayal and a stark warning that our daily habits write a significant part of this grim story.
More related reading
04 · Category
Survival and Prognosis30 stats
01
Median overall survival for untreated metastatic colorectal cancer is 5-6 months
02
5-year overall survival rate for metastatic CRC is 14.9% (US SEER 2014-2020)
03
With first-line FOLFOX + bevacizumab, median PFS is 9.4 months in mCRC
04
Patients with KRAS wild-type mCRC have 28-month median OS vs 20 months mutant
05
Resected liver metastases yield 5-year OS of 57% in selected mCRC patients
06
Left-sided mCRC tumors show 33.3-month median OS vs 20.9 months right-sided
07
Elderly (>75) mCRC patients have 12-month median OS vs 26 months younger
08
MSI-high mCRC has 5-year OS of 71% vs 52% MSS on immunotherapy
09
With regorafenib, median OS extension is 1.4 months in refractory mCRC
10
Lung-only metastases in mCRC confer 40-month median OS post-resection
11
Triple-class therapy (chemo+anti-VEGF+anti-EGFR) yields 38-month OS in RAS wt
12
Peritoneal carcinomatosis in mCRC reduces median OS to 15 months
13
10-year OS post curative metastasectomy in mCRC is 21.5%
14
BRAF V600E mutant mCRC has 11-month median OS vs 26 months wild-type
15
With encorafenib + cetuximab, BRAF mutant mCRC median OS is 15.6 months
16
ECOG PS 0 mCRC patients achieve 32-month OS vs 12 months PS 2
17
HER2-positive mCRC (3%) has 11-month OS on trastuzumab deruxtecan
18
Cytoreductive surgery + HIPEC for peritoneal mCRC gives 41-month median OS
19
Nivolumab in MSI-H/dMMR mCRC yields 49.1-month median OS (ORR 55%)
20
Multi-site metastases (>3 organs) reduce mCRC OS to 14 months
21
Adjuvant chemo post liver resection extends 5-year DFS to 40% in mCRC
22
Fruquintinib in refractory mCRC improves OS by 3.7 months (7.4 vs 4.0)
23
3-year OS in oligometastatic mCRC post SBRT is 57%
24
Elevated LDH (>upper limit) halves mCRC median OS to 13 months
25
Pembrolizumab in MSI-H mCRC: 80% 2-year OS rate
26
CEA >100 ng/mL pre-treatment predicts <18-month OS in 70% mCRC cases
27
RAS/BRAF wt left-sided mCRC on cetuximab has 39-month OS
28
Post two lines therapy, trifluridine-tipiracil extends OS by 2 months (7.1 vs 5.3)
29
5-year cancer-specific survival for resected mCRC lung mets is 42%
30
Bevacizumab beyond progression adds 3.9 months OS in mCRC (11.2 vs 9.8)
Interpretation
Survival and Prognosis Interpretation
A patient's journey with metastatic colorectal cancer hinges on a brutal cascade of ifs—if the tumor is on the left, if mutations are absent, if metastases are few and resectable, if their body is robust, and if the ever-advancing arsenal of treatments arrives in precisely the right sequence, then survival shifts from mere months to potential years, painting a stark portrait of a disease where geography, genetics, and sheer luck are as critical as chemotherapy.
05 · Category
Treatment Efficacy28 stats
01
Median PFS with FOLFOXIRI + bevacizumab is 12.1 months in mCRC
02
Cetuximab + irinotecan in KRAS wt refractory mCRC: ORR 22.5%
03
Encorafenib + cetuximab in BRAF V600E mCRC: ORR 26%, PFS 4.3 months
04
Nivolumab + ipilimumab in MSI-H mCRC: ORR 55%, CR 13%
05
Regorafenib in refractory mCRC: PFS 1.9 months, OS benefit 1.4 months
06
Trifluridine-tipiracil + bevacizumab: PFS 5.6 months vs 4.0 monotherapy
07
Atezolizumab + bevacizumab + chemo in MSS mCRC: ORR 80% early data
08
Fruquintinib monotherapy: ORR 1.5%, but OS 7.4 months in refractory mCRC
09
Panitumumab + FOLFOX: ORR 55%, PFS 10.1 months in RAS wt mCRC
10
TAS-102 in refractory mCRC: DCR 44%, OS 7.1 months
11
Bevacizumab + FOLFOX4: ORR 47%, PFS 9.4 months (AVF2107g)
12
Cetuximab monotherapy: ORR 12.8% in EGFR+ chemorefractory mCRC
13
HER2-targeted tucatinib + trastuzumab: ORR 38.1% in HER2+ mCRC
14
FOLFOXIRI + bevacizumab: ORR 65%, R0 resection rate 61% in unresectable mCRC
15
Pembrolizumab in MSI-H/dMMR mCRC: ORR 40%, DOR 72.9 months median
16
Ziv-aflibercept + FOLFIRI: PFS 6.9 months vs 5.0
17
Margetuximab + pembrolizumab in HER2+ mCRC: ORR 32%
18
Cabozantinib in refractory mCRC: ORR 2%, stable disease 26%
19
Dostarlimab in dMMR mCRC: ORR 43.4%, 84% 12-month DOR
20
Irinotecan + cetuximab: ORR 26.8% in irinotecan-refractory KRAS wt mCRC
21
Lonsurf + bevacizumab: ORR 19.3% in refractory mCRC
22
Onivyde (nal-IRI) + 5-FU/leucovorin: OS 8.5 months in gemr refractory mCRC
23
Batiraxcept + chemo: PFS 10.4 months in first-line mCRC
24
Atezolizumab/bevacizumab + chemo vs bev/chemo: HR 0.72 for PFS
25
Ramucirumab + FOLFIRI: PFS 5.6 months in refractory mCRC
26
Nivolumab monotherapy MSI-H mCRC: ORR 31%, PFS 14.3 months
27
Trastuzumab deruxtecan in HER2+ mCRC: ORR 45.3%
28
FOLFIRI + panitumumab: ORR 57%, PFS 10 months RAS wt
Interpretation
Treatment Efficacy Interpretation
The sobering truth about metastatic colorectal cancer is that even our most celebrated treatment victories often buy patients only precious months, yet the relentless pursuit of more precise, targeted therapies offers glimmers of hope that we are slowly, stubbornly, moving the needle.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Sophie Moreland. (2026, February 13). Metastatic Colorectal Cancer Statistics. Gitnux. https://gitnux.org/metastatic-colorectal-cancer-statistics
MLA
Sophie Moreland. "Metastatic Colorectal Cancer Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/metastatic-colorectal-cancer-statistics.
Chicago
Sophie Moreland. 2026. "Metastatic Colorectal Cancer Statistics." Gitnux. https://gitnux.org/metastatic-colorectal-cancer-statistics.
Sources & references
22 datasets cited across this report · attribution is report-level